Nontricyclic antidepressants: Current trends in children and adolescents

被引:70
作者
Emslie, GJ
Walkup, JT
Pliszka, SR
Ernst, M
机构
[1] Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75235 USA
[2] Johns Hopkins Med Inst, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA
[3] Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA
[4] NIDA, Brain Imaging Ctr, NIH, Baltimore, MD USA
关键词
selective serotonin reuptake inhibitors; monoamine oxidase inhibitors; psychopharmacology; safety; efficacy;
D O I
10.1097/00004583-199905000-00013
中图分类号
B844 [发展心理学(人类心理学)];
学科分类号
040202 ;
摘要
Objectives: First, to review the extant data on the safety and efficacy of the use of nontricyclic antidepressants in children and adolescents; second, to identify the main limitations of our current knowledge in this area; and third, to point to future research directions. Method: A Medline search and a review of previous scientific meetings were conducted; all available reports on the efficacy and safety of nontricyclic antidepressants in children and adolescents were critically reviewed. Results: As in adults, also in children nontricyclic antidepressants are potentially useful in treating a variety of psychiatric disorders. The data supporting their efficacy, however, are quite limited. Obsessive-compulsive disorder is the only psychiatric diagnosis for which pediatric use of selective serotonin reuptake inhibitors has been approved. One placebo-controlled study in children and adolescents with major depression supports the efficacy of fluoxetine. Other clinical trials of nontricyclic antidepressants in depressed adolescents are in progress. Available data indicate that the safety of these medications is good, at least in the short term. Conclusions: The potential usefulness of nontricyclic antidepressants for children and adolescents suffering from a range of disorders is considerable. While information from adults can suggest potential areas of possible efficacy in pediatric patients suffering from similar psychopathology, further research is essential to provide the necessary information on the efficacy, safety, and pharmacokinetics of these medications in children and adolescents.
引用
收藏
页码:517 / 528
页数:12
相关论文
共 117 条
[1]  
Adler LA, 1995, PSYCHOPHARMACOL BULL, V31, P785
[2]  
ALESSI N, 1991, AM J PSYCHIAT, V148, P1605
[3]  
ALEXANDER RC, 1991, J CLIN PSYCHIAT, V52, P88
[4]   CURRENT KNOWLEDGE OF MEDICATIONS FOR THE TREATMENT OF CHILDHOOD ANXIETY DISORDERS [J].
ALLEN, AJ ;
LEONARD, H ;
SWEDO, SE .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1995, 34 (08) :976-986
[5]  
[Anonymous], 1991, J. Child Adolesc. Psychopharmacol, DOI [10.1089/cap.1990.1.193, DOI 10.1089/CAP.1990.1.193]
[6]   THE EFFECTS OF NEFAZODONE ON SLEEP ARCHITECTURE IN DEPRESSION [J].
ARMITAGE, R ;
RUSH, AJ ;
TRIVEDI, M ;
CAIN, J ;
ROFFWARG, HP .
NEUROPSYCHOPHARMACOLOGY, 1994, 10 (02) :123-127
[7]  
BAKISH D, 1993, CLIN NEUROPHARMACOL, V16, pS77
[8]   Venlafaxine: In vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; Comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYPIA2 [J].
Ball, SE ;
Ahern, D ;
Scatina, J ;
Kao, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (06) :619-626
[9]  
BARRICKMAN L, 1991, J AM ACAD CHILD PSY, V30, P762, DOI 10.1097/00004583-199109000-00010
[10]   BUPROPION VERSUS METHYLPHENIDATE IN THE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER [J].
BARRICKMAN, LL ;
PERRY, PJ ;
ALLEN, AJ ;
KUPERMAN, S ;
ARNDT, SV ;
HERRMANN, KJ ;
SCHUMACHER, E .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1995, 34 (05) :649-657